DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 084623
NDA 084623 describes CHLORDIAZEPOXIDE HYDROCHLORIDE, which is a drug marketed by Ascot, Barr, Ferrante, Halsey, Impax Labs, Ivax Sub Teva Pharms, Lederle, Mast Mm, Mylan, Parke Davis, Pioneer Pharms, Purepac Pharm, Roxane, Superpharm, Teva, Upsher-smith Labs, Usl Pharma, Vangard, Watson Labs, and West Ward, and is included in sixty-four NDAs. It is available from twelve suppliers. Additional details are available on the CHLORDIAZEPOXIDE HYDROCHLORIDE profile page.
The generic ingredient in CHLORDIAZEPOXIDE HYDROCHLORIDE is chlordiazepoxide hydrochloride. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the chlordiazepoxide hydrochloride profile page.
The generic ingredient in CHLORDIAZEPOXIDE HYDROCHLORIDE is chlordiazepoxide hydrochloride. There are eight drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the chlordiazepoxide hydrochloride profile page.
Summary for 084623
| Tradename: | CHLORDIAZEPOXIDE HYDROCHLORIDE |
| Applicant: | Usl Pharma |
| Ingredient: | chlordiazepoxide hydrochloride |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
